Department of Cardiothoracic Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya Aichi 466-8550, Japan.
J Transl Med. 2013 Jul 22;11:175. doi: 10.1186/1479-5876-11-175.
Mesenchymal stem cells (MSCs) are known to be capable of suppressing inflammatory responses. We previously reported that intra-abdominal implantation of bone marrow-derived MSCs (BM-MSCs) sheet by laparotomy attenuated angiotensin II (AngII)-induced aortic aneurysm (AA) growth in apolipoprotein E-deficient (apoE-/-) mice through anti-inflammation effects. However, cell delivery by laparotomy is invasive; we here demonstrated the effects of multiple intravenous administrations of BM-MSCs on AngII-induced AA formation.
BM-MSCs were isolated from femurs and tibiae of male apoE-/- mice. Experimental AA was induced by AngII infusion for 28 days in apoE-/- mice. Mice received weekly intravenous administration of BM-MSCs (n=12) or saline (n=10). After 4 weeks, AA formation incidence, aortic diameter, macrophage accumulation, matrix metalloproteinase (MMP)' activity, elastin content, and cytokines were evaluated.
AngII induced AA formation in 100% of the mice in the saline group and 50% in the BM-MSCs treatment group (P < 0.05). A significant decrease of aortic diameter was observed in the BM-MSCs treatment group at ascending and infrarenal levels, which was associated with decreased macrophage infiltration and suppressed activities of MMP-2 and MMP-9 in aortic tissues, as well as a preservation of elastin content of aortic tissues. In addition, interleukin (IL)-1β, IL-6, and monocyte chemotactic protein-1 significantly decreased while insulin-like growth factor-1 and tissue inhibitor of metalloproteinases-2 increased in the aortic tissues of BM-MSCs treatment group.
Multiple intravenous administrations of BM-MSCs attenuated the development of AngII-induced AA in apoE-/- mice and may become a promising alternative therapeutic strategy for AA progression.
间充质干细胞(MSCs)被认为能够抑制炎症反应。我们之前报道过,通过剖腹术将骨髓来源的间充质干细胞(BM-MSCs)片植入腹腔内,可以通过抗炎作用减弱载脂蛋白 E 缺陷(apoE-/-)小鼠的血管紧张素 II(AngII)诱导的主动脉瘤(AA)生长。然而,剖腹术的细胞输送是侵入性的;我们在此展示了多次静脉注射 BM-MSCs 对 AngII 诱导的 AA 形成的影响。
从雄性 apoE-/- 小鼠的股骨和胫骨中分离出 BM-MSCs。apoE-/- 小鼠用 AngII 输注 28 天诱导实验性 AA。小鼠每周接受一次 BM-MSCs(n=12)或生理盐水(n=10)静脉注射。4 周后,评估 AA 形成发生率、主动脉直径、巨噬细胞积累、基质金属蛋白酶(MMP)活性、弹性蛋白含量和细胞因子。
在生理盐水组的 100%小鼠和 BM-MSCs 治疗组的 50%小鼠中,AngII 诱导 AA 形成(P<0.05)。在 BM-MSCs 治疗组中,在升主动脉和肾下主动脉水平观察到主动脉直径显著减小,这与巨噬细胞浸润减少以及主动脉组织中 MMP-2 和 MMP-9 的活性受到抑制以及主动脉组织中的弹性蛋白含量保持有关。此外,主动脉组织中白细胞介素(IL)-1β、IL-6 和单核细胞趋化蛋白-1 显著减少,而胰岛素样生长因子-1 和金属蛋白酶组织抑制剂-2 增加。
多次静脉注射 BM-MSCs 可减轻 apoE-/- 小鼠 AngII 诱导的 AA 的发展,可能成为 AA 进展的一种有前途的替代治疗策略。